Propanc obtains US patent and plans to purchase 100 million USD worth of Ether to support cancer drug development.

[Coin World] Propanc Biopharma (NASDAQ: PPCB) announced that it has obtained a U.S. patent covering its leading cancer therapy PRP clinical dose, enhancing its intellectual property portfolio, bringing its total global patents to 90. At the same time, this biotech company announced plans to acquire $100 million worth of Ethereum over the next 12 months as part of its digital asset diversification strategy to support clinical development while avoiding excessive equity dilution. This dual strategy draws on financial strategies adopted by some companies, combining patent protection with encryption assets to fund drug development. Propanc plans to launch its phase 1B clinical trial for its enzyme-based solid tumor cancer therapy next year.

ETH-0.17%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • 8
  • Repost
  • Share
Comment
0/400
LittleBrat119vip
· 09-22 11:59
With more companies like this, how can ETH not rise?
View OriginalReply0
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)